Dr. Bo-Wei Wang is a biomedical scientist with a Ph.D. and extensive experience in preclinical pharmacology, metabolic research, and translational drug development. He currently serves as a Research Scientist and Project Manager at LaunXP Biomedicine Co., Ltd., where he leads discovery and IND-enabling programs across multiple therapeutic areas. His expertise includes in vitro and in vivo model development, mechanistic studies, and metabolic/adipose-tissue assessments, with a strong commitment to data quality and regulatory compliance. Dr. Wang manages the preclinical evaluation of LXP103, coordinating its design, execution, and data integration to highlight its potential as a safe and durable candidate for weight management and adipose tissue modulation.